Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma

Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma

Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research

We hypothesize that supplementation with Nigella sativa will lead to improved asthma control scores and enhanced pulmonary function parameters in this population.

Inclusion Criteria:

1. Children aged 6-18 years
2. Diagnosed with moderate persistent asthma according to the Global Initiative for Asthma (GINA) 2022 guidelines
3. Receiving stable standard controller therapy (inhaled corticosteroids ± long-acting β2-agonists) for at least 4 weeks prior to enrollment
4. Able to perform reproducible spirometry

Exclusion Criteria:

1. History of severe asthma exacerbation requiring ICU admission in the past 3 months
2. Use of systemic corticosteroids within 4 weeks prior to enrollment
3. Known hypersensitivity to Nigella sativa or its components
4. Other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis)
5. Significant comorbidities (e.g., cardiac, renal, or hepatic disorders)
6. Inability to comply with study procedures